Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | IDH1 R132H |
Therapy | Olaparib + Radiotherapy |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | intrahepatic cholangiocarcinoma | sensitive | Olaparib + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with Lynparza (olaparib) enhanced the sensitivity of an intrahepatic cholangiocarcinoma cell line expressing IDH1 R132H to radiation therapy, resulting in decreased survival in culture and delayed tumor growth and increased survival compared to radiation therapy alone in a cell line xenograft model, with a median overall survival of 60 days vs 47 days, respectively (PMID: 32494639). | 32494639 |
PubMed Id | Reference Title | Details |
---|---|---|
(32494639) | Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. | Full reference... |